• Featured - Will earlier springs throw nature out of step?
• Featured - Depressed people feel more gray than blue
• Featured - Nicotine replacement therapy is over-promoted; most ex-smokers quit unassisted
• Featured - Antiretroviral therapy associated with increase in pregnancy in sub-Saharan Africa
• Featured - Study reveals new details on the dangers of third-hand smoke
• Featured - Biologist solves mystery of tropical grasses' origin
• How Cancer Wreaks Havoc on Bone
• U.S. Officials Plan $78.5 Million Effort to Keep Dangerous Carp Out of Great Lakes
…full story

• BIO chief maps salvage plan for the 12-year umbrella
• Novavax, ROVI end talks over flu vax
• Senate provision could benefit biotech industry
• FDA questions Cell Therapeutics' pixantrone
• Solace shutters Boston-based office
• Incomplete plant inspections prevent Zuplenz approval
• Optimer trial results lead to takeover talks
• Allergan buys Serica Tech
…full story

• A potent suppressor of endometrial cancer is revealed
• Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models
• Method of the future uses single-cell imaging to identify gene interactions
• Inhibiting serotonin in gut could cure osteoporosis
• Virus-free technique enables Stanford scientists to easily make stem cells pluripotent
• Molecular 'firing squad' in mice triggered by overeating destroys metabolism
• BASF and Embrapa’s Cultivance soybeans receive approval for commercial cultivation in Brazil
• Paloma Pharmaceuticals Receives Approval to Enter Phase I Clinical Trials
…full story

• Pfenex, Inc.: Series A $24M
• Circassia, Ltd.: Series C $25M
• Savara Pharmaceuticals, Inc.: Series A $1.4M
• PTC Therapeutics, Inc.: Series E $50M
• Zogenix, Inc.: Series B $20M
• Therasis, Inc.: Series A $12M
• Apnex Medical, Inc.: Series B $14M
• Evolva, SA: Series B $15.3M
…full story

• VA Del. Chris Peace: Support Capital Gains Exclusion for Biotech in Virginia
• Flashback: John Crowley from "Extraordinary Measures" in Virginia
• HGS CEO Cites Virginia as Success in Growing & Attracting Biotech
• Biotechnology Is Part of Jobs and Opporunities Agenda
• VaBIO Hosts "Extraordinary Measures" Movie Night in Richmond
• Virginia Gov. McDonnell proposes more biotech funding
• VA Gov McDonnell: $7.5 Million for Biotech Program
• Va. business leaders put transportation woes on back burner for now, turn to incentives and fairer school funding
…full story

• Vetter Wins the Axia Award
• clinicalprojects international GmbH Announces Further Growth into New Therapeutic and ...
• InVitria Sponsors 2010 Biomanufacturing Summit
• Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of ...
• GATC Biotech Orders Europe’s First HiSeq 2000 for Commercial Use
• Ambry Genetics Announces Launch of StemArray™ Product and Service
• Maik W. Jornitz elected Chair of the Board of the global Parenteral Drug Association
• Kinaxo Extends its Collaboration with Roche
…full story

• Bioscience Day at the Capitol: Patrick Kelly, Biotechnology Industry Association, YouTube Now Posted
• CEO Collar leaves Colorado BioScience Association
• Colorado BioScience Association's CEO moves on
• Archived from Jan 22, 2010 -- BioScience Day at Capitol to showcase industry Jan. 27
• Recap: Bioscience Day at the Capitol
• January 22, 2010 - InDevR Featured in the Boulder County Business Report
• From January 15, 2010 -- Pico Tesla Featured in the Denver Business Journal
• Colorado's Bioscience Industry Leaders and Legislators Focus on 2010 Initiatives At the Annual CBSA 'Bioscience Day at the Capitol'
…full story

• Building a Startup: Focus on Quality from Day One
• Can Biosimilars Be Cheaper?
• Nanoparticles for Diagnosis of Pathogenic Infection
• Downstream Processing of Monoclonal Antibodies
• Can Neurodegenerative Diseases be Cured by Chaperone Induction?
• Protein Chaperones Ensure Structure and Function
• HDP Research Aims at Superbugs
• Notch Inhibitor Peptide Slows Tumor Formation
…full story

• PhRMA wants you!
• Impossible fixes
• PML problems loom for Rituxan
• Pfizer stakes a claim in plant cell–made biopharmaceuticals
• Amylin's $1 billion heavyweight deal
• Peruvian GM advocate faces criminal charges
• EC convenes crisis talks on European biotech sector
• Irish bioethics council axed …full story

• Science Daily Biotech: Prion Protein in Cell Culture The fatal brain disease Creutzfeldt-Jakob in humans, BSE (bovine spongiform encephalopathy) in cattle and scrapie in sheep are so-called prion diseases, whereby one of the body's ... > full story …full story

• In this issue
• Is open innovation the way forward for big pharma?
• 2009 FDA drug approvals
• News in brief
• Deal watch: Celgene acquires Gloucester Pharmaceuticals, gaining approved HDAC inhibitor
• Deal watch: Dipping into Incyte's JAK-pot
• Deal watch: M&A activity in 2009 …full story

• Allos Therapeutics: 08/10/09 Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma …full story

• Affygility: April 23, 2009
• Affygility Solutions releases Potent Compound Safety Self-Assessment Tool
• Affygility Solutions is pleased to announce the release of its Potent Compound Safety Self-Assessment Tool - PCSSAT™ to ensure safe potent compound handling.
• Based on industry expertise, PCSSAT™ allows life science companies the ability to self-evaluate their programs, procedures, and operational practices …full story